Andrew Conway Morris

Dr Conway Morris undertook undergraduate training in Glasgow, UK before moving to Edinburgh to start his training in Anaesthesia and Intensive Care.  Whilst in Edinburgh he developed an interest in ICU-acquired infections and studied for a PhD in critical care immunology and its impact on nosocomial infections supervised by Professors John Simpson and Timothy Walsh.  He moved to Cambridge to complete his post-graduate training in Anaesthesia and ICM and to undertake post-doctoral research with Professor Edwin Chilvers.  His work continues to focus on immune failure in critical illness and nosocomial infection. 

He published the first study identifying C5a as a key mediator of neutrophil dysfunction in critical illness.  This has led to subsequent work developing clinically useable markers for immune dysfunction, a clinical trial of immunomodulatory therapy and exploration of the intracellular signalling pathways which underpin these effects.  He has also developed a number of diagnostics for nosocomial infection, including the host response test recently evaluated in the VAP-RAPID trial, and several pathogen-focussed molecular diagnostic platforms.  He is currently a Wellcome Trust Clinical Research Career Development fellow at the University of Cambridge and Consultant in Intensive Care Medicine in the John V Farman Intensive Care Unit, Addenbrooke’s Hospital, Cambridge, UK.  He is the incoming Deputy Chair of the European Society of Intensive Care Medicine’s Infection section.

Andrew Conway Morris.png
SpeakeriDigital Ltd